DJIA: 18,082.97  +45.00 (0.25%) | NASDAQ: 5,057.679  -2.567 (-0.05%) | S&P 500: 2,112.45  +3.53 (0.17%) Markets close in 1 hr 42 mins

  • Show Article Details

    Analysts at Goldman Sachs say money would be better spent pursuing deals overseas. U.S. companies are expected to return roughly $1 trillion in cash to investors this year via stock buybacks and dividends, up 18% from 2014. But that money would be better spent pursuing overseas deals than rewarding shareholders in the short term, according to analysts at Goldman Sachs. "Given current historically high equity valuation and a strong U.S. dollar, for many firms a superior strategic...

  • Show Article Details

    Canadian intermediate producer TORC Oil & Gas Ltd (VREYF) is buying light oil assets from Surge Energy Inc in the Canadian Bakken region of southeast Saskatchewan and Manitoba for C$430 million, Surge said on Monday. Calgary-based TORC said in a statement it would acquire the assets from an independent Canadian oil producer.

  • Show Article Details

    AB Acquisition LLC, the holding company that owns Safeway Inc, has hired IPO bankers to plan an initial public offering for the grocery store chain later this year, CNBC reported, citing sources with knowledge of the matter. The IPO would raise more than $500 million, but the timing and size of the offering remains fluid, CNBC cited the sources as saying.

  • Show Article Details

    Teva issues calm response to Mylan's sharp rejection. Passive, say hello to aggressive. That might be the best tagline as generic-drug maker Teva Pharmaceutical Industries Ltd. offered what appeared to be a rather restrained response to Mylan N.V.' s sharp-tongued rejection of Teva's $43 billion buyout overture.

  • Show Article Details

    Teva Pharmaceuticals shares are down 2.33% to $62.91 in trading on Monday after Mylan officially rejected the company's $82 per share bid for the company, in a statement released earlier today.The half cash half stock bid values Mylan at about $43 billion and while Mylan has rejected the offer, Teva said today that it is still committed to partnering with the company."While we are disappointed ...

  • Show Article Details

    TIG Advisors LLC, an investment firm that holds shares in Altera Corp (ALTR), challenged the company's board director nomination on Monday over its refusal to engage with Intel Corp (INTC) about a potential merger. TIG Advisors is the first shareholder to go on the record in a bid to put pressure Altera.

  • Show Article Details

    Teva Pharmaceutical Industries Ltd. (TEVA) said Monday it was "fully committed" to its $43 billion bid for fellow generic drug maker Mylan NV (MYL), despite Mylan's rejection, issued earlier in the day. Teva maintained the bid, involving an equal mix of cash and stock, is "extremely attractive" for Mylan shareholders, noting that it represents a 48.3% premium to the company's shares on March 10, just before speculation about a possible combination surfaced. Earlier on Monday, Mylan issued a harsh...

  • Show Article Details

    U.S. proxy advisory firm ISS has recommended DuPont (DD) shareholders vote in favor of activist investor Nelson Peltz and another nominee joining the chemical conglomerate's board, the Wall Street Journal reported. Peltz's hedge fund Trian Fund Management, DuPont's (DD) fifth-largest shareholder with a 2.7 percent stake, has for months criticized DuPont's (DD) underperformance.

  • Show Article Details

    Mylan shares are down 2.36% to $74.25 in early market trading on Monday after the drug manufacturer announced that its board unanimously rejected rival Teva's unsolicited $40 billion bid for the company.This rejection comes one session after Mylan's unsolicited $33 billion takeover attempt of Perrigo (PRGO) fell flat when Perrigo (PRGO) rejected the offer saying that it undervalued the company and its assets.

  • Show Article Details

    Mylan N.V.' s stock slumped 3% in morning trade Monday, after the drug maker said its board of directors unanimously rejected Teva Pharmaceutical's unsolicited buyout bid. Mylan said it not only believes the bid Teva made early last week, which would value Mylan at about $40 billion, did not meet any of the key criteria that would cause the company to depart from its current course. "After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly...

  • Show Article Details

    ZF Friedrichshafen AG. * Successfully places U.S. dollar denominated bonds with overall volume of $3.5 billion as well euro-denominated bonds worth 2.25 billion eur. * To use proceeds of bond issuances for TRW takeover Further company coverage: